These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2513139)

  • 21. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
    Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
    J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
    Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
    Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma.
    Teicher BA; Chen YN; Ara G; Emi Y; Kakeji Y; Maehara Y; Keyes S; Northey D
    Int J Cancer; 1996 Sep; 67(6):864-70. PubMed ID: 8824560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.
    Williams SF; Bitran JD; Kaminer L; Westbrook C; Jacobs R; Ashenhurst J; Robin E; Purl S; Beschorner J; Schroeder C
    J Clin Oncol; 1987 Feb; 5(2):260-5. PubMed ID: 3027271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose thiotepa alone and in combination regimens with bone marrow support.
    Antman K; Eder JP; Elias A; Ayash L; Shea TC; Weissman L; Critchlow J; Schryber SM; Begg C; Teicher BA
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):33-8. PubMed ID: 2106166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
    Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
    In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of ultrasonic hyperthermia with two alkylating agents in a murine bladder tumor.
    Longo FW; Tomashefsky P; Rivin BD; Tannenbaum M
    Cancer Res; 1983 Jul; 43(7):3231-5. PubMed ID: 6406056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of DNA repair in cells treated with a combination of alkylating agents.
    Frankfurt OS; Seckinger D; Sugarbaker EV
    Anticancer Res; 1993; 13(4):947-52. PubMed ID: 8352564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosing of thioTEPA for myeloablative therapy.
    Przepiorka D; Madden T; Ippoliti C; Estrov Z; Dimopoulos M
    Cancer Chemother Pharmacol; 1995; 37(1-2):155-60. PubMed ID: 7497586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of resistance and therapeutic synergism among alkylating agents.
    Schabel FM; Trader MW; Laster WR; Wheeler GP; Witt MH
    Antibiot Chemother (1971); 1978; 23():200-15. PubMed ID: 348078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA; Bernal SD; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
    Ayash L; Korbut T; Herman TS; Teicher BA
    Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
    Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
    J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Papadopoulou MV; Ji M; Bloomer WD
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
    Papadopoulou MV; Ji M; Bloomer WD
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):775-9. PubMed ID: 9845094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of cytotoxicity of single dose and infusion of alkylating agents.
    Valeriote F; Vietti T
    Cancer Drug Deliv; 1985; 2(1):11-8. PubMed ID: 4052923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
    Parra K; Valenzuela P; Lerma N; Gallegos A; Reza LC; Rodriguez G; Emmenegger U; Di Desidero T; Bocci G; Felder MS; Manciu M; Kirken RA; Francia G
    Br J Cancer; 2017 Jan; 116(3):324-334. PubMed ID: 28056464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.